Sleep Initiation and Maintenance DisordersPhase 2NCT00650871
A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia
A Phase 2 study testing GW679769 in people with Sleep Initiation and Maintenance Disorders, run by GlaxoSmithKline at 7 sites in United States.
Trial summary
A study to investigate the effects of GW679769 on sleep and cognition. Potential subjects participate in a clinical screening visit and a two-night PSG recording session in the sleep laboratory. Read more about this study
- Who is it for?
- Ages 18 to 64 years
- Conditions the study is for
- Sleep Initiation and Maintenance Disorders
- What is being tested?
- GW679769
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 48 participants
- Where
- 7 sitesUnited States
- Study dates
- 30 Jul 2004to 30 Aug 2005
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Healthy male and female subjects with primary insomnia with normal EG may be eligible for inclusion.
Who cannot join
- clinically significant physical or psychiatric illness or abnormal sleep patterns.
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
United States7 sites
GSK Investigational Site
Atlanta, Georgia, 30342
GSK Investigational Site
Cincinnati, Ohio, 45246
GSK Investigational Site
Durham, North Carolina, 27705
GSK Investigational Site
New York, New York, 10025
GSK Investigational Site
Philadelphia, Pennsylvania, 19107
GSK Investigational Site
San Diego, California, 92123
GSK Investigational Site
Winston-Salem, North Carolina, 27157
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of GW679769 (30mg and 90mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects With Primary Insomnia
A study to investigate the effects of GW679769 on sleep and cognition. Potential subjects participate in a clinical screening visit and a two-night PSG recording session in the sleep laboratory. Eligible subjects then participate in three separate two-night PSG sessions in which they are randomized to receive placebo or one of two doses of GW679769 60 minutes prior to bedtime, one treatment for each session in a balanced order. Each treatment session is separated by a two-week drug-free period and occur on the same day of the week. A safety follow-up visit occurs 2 weeks after the last treatment session.
- Being tested
- GW679769, Placebo
- Keywords
- sleep,, polysomnography., GW679769,, primary insomnia,, cognitive function,
- Medical subject headings
- Sleep Initiation and Maintenance Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GW679769Drug
PlaceboDrug
Also called GW679769
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Wake time after sleep onset (WASO) derived from PSG recording
WASO was measured from persistent sleep onset to lights on. It was calculated as number of wake epochs from persistent sleep onset to lights on divided by 2. WASO measures was analyzed using a mixed effect model with session and treatment as fixed effect and participants as random effect.
Measured: Night 1 and 2 of each treatment period (Approximately up to 31 Days)
Secondary outcomes (20)
Mean total sleep time (TST) as objective PSG measures of sleep continuity
TST was defined as duration of Rapid Eye Movement (REM) plus non-REM (NREM)(Stage 1, Stage 2, Stages 3/4) sleep from lights off to lights on. It was calculated as number of REM plus NREM (Stage 1, Stage 2, Stages 3/4) epochs from lights off to lights on divided by 2.
Measured: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Mean latency to persistent sleep (LPS) as objective PSG measures of sleep continuity
LPS was measured from lights off to the first epoch of 20 consecutive non-wake epochs (sleep onset).It was calculated as number of epochs from lights off to the first of 20 consecutive non-wake epochs (sleep onset) divided by 2.
Measured: Night 1 and 2 of each treatment period (approximately 31 days)
Mean wake during sleep (WDS) as objective PSG measures of sleep continuity
WDS was the duration, in min, of wakefulness from persistent sleep onset to final epoch of sleep (stage 1, 2, 3/4, or REM), and corresponds to WDS. WDS was defined as duration of wakefulness from persistent sleep onset to final epoch of sleep (stage 1, 2, 3/4 or REM) (min). An awakening was defined as a PSG recording of at least one wake epoch, bracketed by an epoch of stage 1, 2, or stage 3/4 of NREM sleep or REM sleep. The score was derived by a central PSG reader and was analyzed as the mean of the PSG WDS recordings obtained on two consecutive nights.
Measured: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Mean wake after sleep (WAS) as objective PSG measures of sleep continuity
WAS defined as the duration of wakefulness, in min, from final epoch of sleep to lights on The score was derived by a central PSG reader and was analyzed as the mean of the PSG WAS recordings obtained on two consecutive nights. If only one assessment was present for a particular PSG session, the score from that one assessment was used. The overall WAS for night 1 and 2 was reported.
Measured: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Mean number of 1 minute awakenings during sleep as objective PSG measures of sleep continuity
Number of periods of awakening from persistent sleep onset to lights on were recorded. Number of times after persistent sleep onset that there was a wake entry on the PSG recording of at least 1 minute duration (at least 2 consecutive wake epochs). Pairs of awakenings were separated an epoch of NREM sleep or REM sleep. Two wake entries of at least one minute separated by stage 1 sleep was considered as a single awakening.
Measured: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Total Time in NREM Stage 1 and stage 2 as objective PSG measures of sleep structure
NREM sleep time was defined as the duration (in min) of NREM sleep during time in bed. The scores were derived by a central PSG reader and was analyzed as the mean of the PSG NREM recordings obtained on two consecutive nights.Total Time in NREM Stage 1 and stage 2 as objective PSG measures of sleep structure were recorded on night 1 and 2 and mean over the two nights was reported.
Measured: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Total Time in Slow Wave Sleep (SWS) as objective PSG measures of sleep structure
SWS was defined as the duration, in min, of stage 3 or 4 duration during time in bed. Total time in SWS as objective PSG measures of sleep structure was recorded on night 1 and 2 and mean over the two nights was reported.
Measured: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Total Time in REM as objective PSG measures of sleep structure
REM sleep time was also known as stage REM duration. It was defined as the number of minutes of stage REM during time in bed. Time in REM as objective PSG measures of sleep structure was recorded on night 1 and 2 and mean over the two nights was reported.
Measured: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Latency to REM as objective PSG measures of sleep structure
Latency to REM as objective PSG measures of sleep structure was recorded on night 1 and 2 and mean over the two nights was reported.
Measured: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Total sleep time (TST) as parameter of subjective post-sleep questionnaire
TST was the duration in min of REM plus NREM (Stage 1, Stage 2, Stages 3/4) sleep from lights off to lights on obtained on two consecutive nights of each PSG session. It was calculated as the number of REM plus NREM (Stage 1, Stage 2, Stages 3/4) epochs from lights off to lights on that is during Time in Bed (TIB). TST as parameter of subjective post-sleep questionnaire was recorded in response to the question, How long (total hours and minutes) do you think you slept last night? The questionnaire was reported by the participants on the next day of the PSG nights 1 and 2 and mean over the two nights was reported.
Measured: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
WASO as parameter of subjective post-sleep questionnaire
WASO was defined as the amount of time awake after persistent sleep onset to lights on. An awakening was defined as a PSG recording of at least one wake epoch, bracketed by an epoch of stage 1, 2, or stage 3/4 of NREM sleep or REM sleep. WASO was calculated as summation of number of WAS and number of WDS. WASO as parameter of subjective post-sleep questionnaire was assessed from response of the question Did you wake up during the night? The questionnaire was reported by the participants on the next day of the PSG nights 1 and 2 and mean over the two nights was reported.
Measured: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Sleep onset latency (SOL) as parameter of subjective post-sleep questionnaire
SOL is the time required to fall asleep. SOL as parameter of subjective post-sleep questionnaire was recorded in response to the question, How long do you think it took you to fall asleep last night? The questionnaire was reported by the participants on the next day of the PSG nights 1 and 2 and mean over the two nights was reported.
Measured: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Number of awakenings as parameter of subjective post-sleep questionnaire
Number of awakenings was subjective (participant-rated) measurement of number of awakening after sleep onset. Number of awakenings as parameter of subjective post-sleep questionnaire was recorded in response to the question, How many times do you think you woke up? The questionnaire was reported by the participants on the next day of the PSG nights 1 and 2 and mean over the two nights was reported.
Measured: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Sleep quality (SQ) as parameter of subjective post-sleep questionnaire
SQ as parameter of subjective post-sleep questionnaire was recorded in response to the question, How would you describe the quality of your sleep last night? The responses from participants were recorded as very poor = 1, poor = 2, average= 3,good= 4, very good= 5 indicating the SQ. The questionnaire was reported by the participants on the next day of the PSG nights 1 and 2 and mean over the two nights was reported.
Measured: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Digit symbol substitution test (DSST) as a measure of daytime cognitive function
DSST was a widely used measure of performance impairment. It is a typical test of association involved in substituting symbols for digits over a period of time. The number of correct signs substituted was taken as the score. Participants marked a geometric pattern associated with one of the digits displayed on a computer screen. Participants had 90 seconds to match as many geometric patterns as possible. The dependent measure were the number of patterns the participant were able to mark correctly (i.e., number of trials correct). Minimum possible score is 0= impaired cognitive function, there was no upper limit of the score. Higher the score indicated betterment in the daytime cognitive function. Mean DSST was calculated from the observations recorded on days followed by first and second PSG nights and mean over the two nights was reported.
Measured: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Mean Hopkins Verbal Learning Test-Revised (HVLT-R) score including total recall and delayed recall as a measure of Daytime Cognitive Function
HVLT-R assesses verbal learning and memory. It comprised of four subscales including total recall, delayed recall, retention score, and recognition discrimination index. The total recall score was the number of correctly reported words in each of the 3 learning trials and the score ranged from 0 to 36. The delayed recall score was the number of correctly reported words in the delayed recall test and the score ranged from 0 to 12. The retention score represented the score on the delayed recall test divided by the higher of the recall scores from learning trials 2 and 3, multiplied by 100. It was practically ranged from 0 to 100. Higher score indicated betterment in the daytime cognitive function. The recognition discrimination index (RDI) was calculated by subtracting the total false positives score (semantically-related plus semantically un-related) from the total true-positives score obtained in the delayed recognition test).
Measured: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
HVLT-R (Retention %) as a measure of daytime Cognitive Function
The HVLT-R offers a brief assessment of verbal learning and memory (recognition and recall) and its use had been validated with brain-disordered populations. Eight distinct forms of the HVLT-R were available, eliminating practice effects on repeated administrations. Each form consists of a list of 12 nouns (targets) with four words drawn from each of three semantic categories. The semantic categories differ across the eight forms, but the forms were very similar in their psychometric properties. The HVLT-R tasks included three learning trials, a delayed recall trial (20-25 minute delay), and a yes/no delayed recognition trial. This latter trial consists of a randomized list that includes the 12 target words and 12 non-target words, 6 of which are drawn from the same semantic categories as the targets. Mean percent retention of the target words was measured as a daytime cognitive function and mean over the three measures recorded at Night 1, Day 1 and 2 are reported.
Measured: Night 1, Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
HVLT-R (Recognition Discrimination Index [RDI]) as a measure of daytime Cognitive Function
The HVLT-R offers a brief assessment of verbal learning and memory (recognition and recall) and its use had been validated with brain-disordered populations. Eight distinct forms of the HVLT-R were available, eliminating practice effects on repeated administrations. Each form consists of a list of 12 nouns (targets) with four words drawn from each of three semantic categories. The semantic categories differ across the eight forms, but the forms were very similar in their psychometric properties. The HVLT-R tasks included three learning trials, a delayed recall trial (20-25 minute delay), and a yes/no delayed recognition trial. This latter trial consists of a randomized list that includes the 12 target words and 12 non-target words, 6 of which are drawn from the same semantic categories as the targets. Recognition Discrimination Index of the target words was measured as a daytime cognitive function and mean over the three measures recorded at Night 1, Day 1 and 2 are reported.
Measured: Night 1, Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Leeds Sleep Evaluation Questionnaire as scales for sleepiness/alertness
LSEQ had been used to monitor subjectively perceived changes in sleep during psychopharmacological investigation involving a variety of psychoactive agents. The questionnaire contains ten self-rating 100-mm-line analogue questions pertaining to four consecutive aspects of sleep: getting to sleep (GTS), QOS, awakening from sleep (AFS) and behaviour following wakefulness (BFW). Scores on the four LSEQ subscales vary between 100 (the largest possible positive change experienced after drug administration) and 0 (the largest possible negative change experienced after drug administration).
Measured: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Stanford Sleepiness Scale as scales for sleepiness/alertness
Stanford Sleepiness Scale was assessed using the sleep evaluation questionnaire on Day 1 and 7 prior to dosing and at approximately 1 hour intervals after dosing until discharge from the clinic. It was rated on a seven point scale (1-7), where lower score indicates active and higher score indicates sleep onset soon; 1: feeling active, vital, alert, or wide awake, 2: functioning at high levels, but not at peak; able to concentrate, 3: awake, but relaxed; responsive but not fully alert, 4: somewhat foggy, let down, 5: foggy; losing interest in remaining awake; slowed down, 6: sleepy, woozy, fighting sleep; prefer to lie down, 7: no longer fighting sleep, sleep onset soon; having dream-like thoughts and X: asleep. The mean over Day 1 and Day 2 post PSG nights are reported.
Measured: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2008 (estimated)
- Study start30 Jul 2004
- Primary completion30 Aug 2005
- Study completion30 Aug 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sleep Initiation and Maintenance DisordersStudies of the same condition, open and under way.
- More trials run by GlaxoSmithKlineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Crossover
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- GlaxoSmithKline
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, GlaxoSmithKline
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00650871
- Sponsor's protocol ID
- GW679769/903
- Status last verified
- Aug 2017
- First submitted
- 31 Mar 2008
- Last updated
- 8 Aug 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of GW679769 (30mg and 90mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects With Primary Insomnia
- ClinicalTrials.gov ID
- NCT00650871
- Acronym / sponsor ID
- GW679769/903
- Keywords
- sleep,, polysomnography., GW679769,, primary insomnia,, cognitive function,
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- GlaxoSmithKlineIndustry (pharma, biotech, devices)
- Study start
- 30 Jul 2004 (actual)
- Primary completion
- 30 Aug 2005 (actual)
- Study completion
- 30 Aug 2005 (actual)
- First posted
- 2 Apr 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A study to investigate the effects of GW679769 on sleep and cognition. Potential subjects participate in a clinical screening visit and a two-night PSG recording session in the sleep laboratory. Eligible subjects then participate in three separate two-night PSG sessions in which they are randomized to receive placebo or one of two doses of GW679769 60 minutes prior to bedtime, one treatment for each session in a balanced order. Each treatment session is separated by a two-week drug-free period and occur on the same day of the week. A safety follow-up visit occurs 2 weeks after the last treatment session.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Crossover
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Healthy male and female subjects with primary insomnia with normal EG may be eligible for inclusion.
Key exclusion criteria (1 listed)
- clinically significant physical or psychiatric illness or abnormal sleep patterns.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GW679769 | Drug | – |
| PlaceboAlso: GW679769 | Drug | – |
Primary outcome
Mean Wake time after sleep onset (WASO) derived from PSG recording
Time frame: Night 1 and 2 of each treatment period (Approximately up to 31 Days)
WASO was measured from persistent sleep onset to lights on. It was calculated as number of wake epochs from persistent sleep onset to lights on divided by 2. WASO measures was analyzed using a mixed effect model with session and treatment as fixed effect and participants as random effect.
20 secondary outcomes
Mean total sleep time (TST) as objective PSG measures of sleep continuity
Time frame: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Mean latency to persistent sleep (LPS) as objective PSG measures of sleep continuity
Time frame: Night 1 and 2 of each treatment period (approximately 31 days)
Mean wake during sleep (WDS) as objective PSG measures of sleep continuity
Time frame: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Mean wake after sleep (WAS) as objective PSG measures of sleep continuity
Time frame: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Mean number of 1 minute awakenings during sleep as objective PSG measures of sleep continuity
Time frame: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Total Time in NREM Stage 1 and stage 2 as objective PSG measures of sleep structure
Time frame: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Total Time in Slow Wave Sleep (SWS) as objective PSG measures of sleep structure
Time frame: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Total Time in REM as objective PSG measures of sleep structure
Time frame: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Latency to REM as objective PSG measures of sleep structure
Time frame: Night 1 and 2 of each treatment period (Approximately up to 31 days)
Total sleep time (TST) as parameter of subjective post-sleep questionnaire
Time frame: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
WASO as parameter of subjective post-sleep questionnaire
Time frame: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Sleep onset latency (SOL) as parameter of subjective post-sleep questionnaire
Time frame: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Number of awakenings as parameter of subjective post-sleep questionnaire
Time frame: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Sleep quality (SQ) as parameter of subjective post-sleep questionnaire
Time frame: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Digit symbol substitution test (DSST) as a measure of daytime cognitive function
Time frame: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Mean Hopkins Verbal Learning Test-Revised (HVLT-R) score including total recall and delayed recall as a measure of Daytime Cognitive Function
Time frame: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
HVLT-R (Retention %) as a measure of daytime Cognitive Function
Time frame: Night 1, Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
HVLT-R (Recognition Discrimination Index [RDI]) as a measure of daytime Cognitive Function
Time frame: Night 1, Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Leeds Sleep Evaluation Questionnaire as scales for sleepiness/alertness
Time frame: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Stanford Sleepiness Scale as scales for sleepiness/alertness
Time frame: Day 1 and 2 post PSG of each treatment period (Approximately up to 31 days)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Aug 2017.
Related trials for Sleep Initiation and Maintenance Disorders
Recruiting
Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness
Nocturia, Insomnia
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Recruiting
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Recruiting
Treating Insomnia in Mild Cognitive Impairment
Mild Cognitive Impairment (MCI), Insomnia
RecruitingPhase 4
The Effects of Orexin Antagonism on Fear Extinction in PTSD
Insomnia, PTSD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials study director
GlaxoSmithKline
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing GW679769 in people with Sleep Initiation and Maintenance Disorders, run by GlaxoSmithKline at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Wake time after sleep onset (WASO) derived from PSG recording (time frame: Night 1 and 2 of each treatment period (Approximately up to 31 Days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Aug 2017.